The U.S. Food and Drug Administration’s fiscal year 2027 budget justification includes more than 20 legislative proposals spanning drug and biologic approval pathways, supply chain oversight, advertising standards and enforcement authorities. The full package addresses topics ranging from food safety to tobacco regulation, but the subset of proposals most relevant to life science investors include initiatives that would streamline biosimilar and biologic development, create new pathways for complex generics and early-stage clinical programs, strengthen supply chain transparency and enforcement, and incentivize domestic manufacturing. For middle-market private equity firms with life sciences exposure, these initiatives carry substantial implications.
Read the full article: FDA’s FY 2027 Legislative Proposals Include Game Changers for Life Science Private Equity //
Source: https://www.mcguirewoods.com/client-resources/alerts/2026/4/fdas-fy-2027-legislative-proposals-include-game-changers-for-life-science-private-equity/